All news and presentations

9.21.23

Accent Therapeutics Bolsters Leadership Team with Key Executive Hires

Read More

8.23.23

Publication: "Development of assays to support identification and characterization of modulators of DExH-box helicase DHX9" (SLAS Discovery)

Read More

4.16.23

Accent Therapeutics Presents Data Supporting DHX9 Inhibition as a Novel Therapeutic Modality at American Association for Cancer Research (AACR) Annual Meeting 2023

Read More

4.16.23

Accent Presents: "Targeting DHX9 Inhibition as a Novel Therapeutic Modality in Microsatellite Instable Colorectal Cancer" (AACR 2023)

Read More

4.6.23

Accent Therapeutics to Present Data Supporting DHX9 Inhibition as a Novel Therapeutic Modality at American Association for Cancer Research (AACR) Annual Meeting 2023

Read More

3.2.23

Accent Presents: “Discovery of Small Molecule Inhibitors of ADAR1” (GRC 2023) Poster

Read More

3.2.23

Accent Presents: “Development of Assays to Support Identification and Characterization of Modulators of DEAH-Box Helicase DHX9” (SLAS2023)

Read More

10.18.21

Ipsen Adds Another Program Into Its Pre-clinical R&D; Oncology Pipeline Through an Exclusive Worldwide Collaboration With Accent Therapeutics, Targeting the RNA Modifying Protein, METTL3

Read More

6.4.2020

Accent Therapeutics and AstraZeneca to Discover and Develop Novel Cancer Therapeutics in New Collaboration

Read More

4.23.2020

Accent Therapeutics Announces $63 Million Series B Financing to Advance Novel, Precision Cancer Therapies Targeting Rna-modifying Proteins

Read More

9.3.2019

Accent Therapeutics Appoints Shakti Narayan as Chief Executive Officer

Read More

5.18.2018

Accent Therapeutics Announces Company Launch With $40 Million Series A Financing for Novel, Precision Cancer Treatments Targeting Rna-modifying Proteins

Read More